David Hsiehchen

University of Texas Southwestern Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Background Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response and clinical decision-making. We characterized the epidemiology, clinical impact, and molecular determinants of pseudo-stability/progression after atezolizumab with and without bevacizumab across several histologies. Methods Post hoc individual-level analysis of 2980 patients across eight randomized trials of atezolizumab in non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma. Results Analyses of the temporal characteristics of atypical responses revealed two distinct patterns including primary and secondary pseudo-stability/progression. Primary pseudo-stability/progression is characterized by initial disease progression and subsequent regression, which occurs in 7.7%–12.5% of patients according to cancer type. In contrast, secondary progression is characterized by initial disease control with subsequent radiographic progression followed by tumor regression, and this occurs in 4.4%–10.8% of patients according to cancer type. Compared with patients matched by the same initial radiographic response, primary and secondary pseudo-stability/progression could be associated with similar or inferior overall survival outcomes depending on the cancer type and classification of the initial tumor response. Exploratory analyses indicate that clinical factors are not predictive of atypical responses, but pseudo-stability/progression could be associated with distinct genomic alterations including TSC1/2 in RCC. Conclusions Primary and secondary pseudo-stability/progression occur in a non-trivial proportion of patients across cancer types. Outcomes after pseudo-stability/progression are dependent on cancer type and initial response. Uncovering the clinical and molecular features of pseudo-stability/progression subtypes may guide treatment decisions and identify patients who may benefit from continued immunotherapy despite radiographic progression.

Year:

2026

Tumor burden may have opposing influences on immunotherapy outcomes by enhancing neoantigen load or imposing barriers to immune responses. Whether tumor burden is a specific determinant of immunotherapy benefit or a general prognostic factor irrespective of drug mechanism remains ambiguous. We performed a post hoc individual patient-level data analysis of eight prospective trials, including patients with non–small cell lung cancer, hepatocellular carcinoma (HCC), bladder cancer, and renal cell carcinoma to determine the association between tumor burden and immunotherapy and conventional therapy efficacy. Objective response rates were higher among patients with low tumor burden treated with either atezolizumab or conventional therapies. Low tumor burden was also associated with improved progression-free survival in most cancer types and overall survival in all cancer types irrespective of treatment class. Tumor burden effects were dose-dependent across cancer types. An exception to this was in HCC, in which sorafenib treatment was uniquely associated with improved antitumor effects in high tumor burden cancers. Comparisons of outcomes within tumor burden strata showed that atezolizumab is superior to conventional therapy in improving overall survival but not progression-free survival in both high and low tumor burden patients compared with conventional therapies in non–small cell lung cancer, HCC, and bladder cancer. These findings demonstrate that tumor burden is a histology-agnostic and dose-related prognostic factor rather than an immunotherapy-specific predictive biomarker. Cross-treatment analyses suggest that surrogate endpoints may inadequately account for the detrimental impact of tumor burden, with implications for nonrandomized studies and early-phase trials, particularly in which variations in tumor burden exist in the underlying population. Significance: Tumor burden is not a specific predictive marker of immunotherapy benefit but has substantial prognostic effects across cancer types and treatment classes. These results highlight the importance and broad applicability of tumor burden as stratification or selection markers in trial design, especially because surrogate endpoints do not wholly capture the detrimental effects of tumor burden on overall survival.

Year:

2025

Tumor burden may have opposing influences on immunotherapy outcomes by enhancing neoantigen load or imposing barriers to immune responses. Whether tumor burden is a specific determinant of immunotherapy benefit or a general prognostic factor irrespective of drug mechanism remains ambiguous. We performed a post hoc individual patient-level data analysis of eight prospective trials, including patients with non–small cell lung cancer, hepatocellular carcinoma (HCC), bladder cancer, and renal cell carcinoma to determine the association between tumor burden and immunotherapy and conventional therapy efficacy. Objective response rates were higher among patients with low tumor burden treated with either atezolizumab or conventional therapies. Low tumor burden was also associated with improved progression-free survival in most cancer types and overall survival in all cancer types irrespective of treatment class. Tumor burden effects were dose-dependent across cancer types. An exception to this was in HCC, in which sorafenib treatment was uniquely associated with improved antitumor effects in high tumor burden cancers. Comparisons of outcomes within tumor burden strata showed that atezolizumab is superior to conventional therapy in improving overall survival but not progression-free survival in both high and low tumor burden patients compared with conventional therapies in non–small cell lung cancer, HCC, and bladder cancer. These findings demonstrate that tumor burden is a histology-agnostic and dose-related prognostic factor rather than an immunotherapy-specific predictive biomarker. Cross-treatment analyses suggest that surrogate endpoints may inadequately account for the detrimental impact of tumor burden, with implications for nonrandomized studies and early-phase trials, particularly in which variations in tumor burden exist in the underlying population. Significance: Tumor burden is not a specific predictive marker of immunotherapy benefit but has substantial prognostic effects across cancer types and treatment classes. These results highlight the importance and broad applicability of tumor burden as stratification or selection markers in trial design, especially because surrogate endpoints do not wholly capture the detrimental effects of tumor burden on overall survival.

Year:

2025

Study Outcomes. Studies grouped by survival, early stage at diagnosis and treatment type. Underline studies were used in analysis of ICC alone. Overall Survival (OS), Extrahepatic Cholangiocarcinoma (ECC), Surveillance, Epidemiology, and End Results (SEER), Memorial Sloan-Kettering (MSK), Texas Cancer Registry (TCR), National Cancer Database (NCDB), Indiana Cancer Registry (ICR), National Inpatient Sample (NIS), University of Michigan (UM) Queen’s Medical Center of Hawaii (HI)

Year:

2025

Background: Cholangiocarcinoma (CCA) is an increasing cause of mortality in the United States; however, the burden of CCA disproportionately affects racial and ethnic minority groups. We aimed to characterize racial and ethnic differences in stage, treatment, and survival among patients with CCA. Methods: We systematically searched MEDLINE and Embase through March 2023 for all studies reporting clinical outcomes among patients with CCA stratified by race and ethnicity. We calculated pooled HRs using the DerSimonian and Laird method for a random-effects model. Results: Of 292 articles, 16 met inclusion criteria ( n = 248,109 patients). Among six studies ( n = 87,938) reporting overall survival, Black patients had worse survival [pooled HR, 1.05; 95% confidence interval (CI), 1.01–1.10], whereas Hispanic (pooled HR, 0.86; 95% CI, 0.83–0.89) and Asian/Pacific Islander (pooled HR, 0.88; 95% CI, 0.85–0.90) patients had better survival than White patients. Compared with White patients, Black and Hispanic patients were less likely to present at an early stage, and Black patients were less likely to undergo resection (pooled OR, 0.69; 95% CI, 0.63–0.75). The limitations of studies were lack of granularity on subtype and risk of residual confounding. Conclusions: There are racial and ethnic differences in CCA prognosis in the United States, with Black patients having worse survival and Hispanic and Asian patients having better survival than White patients. Studies are needed to identify actionable factors underlying this disparity to promote health equity and improve outcomes for patients. Impact: There exist racial discrepancies in survival and treatment for CCA; more studies are needed to better understand the extent and causes of discrepancies.

Year:

2025

Flow diagram for study selection. Studies were identified through keyword search of MEDLINE and OVID, abstracts and full text were sequentially reviewed by two separate reviewers. Relevant articles were further reviewed to discard overlapping studies.

Year:

2025

Kartung-Knell-Sidik-Jonkmann Forest Plots. (A) Hazard Ratios (HRs) for overall survival comparing Black vs. White patients. (B) HRs for overall survival HRs comparing Hispanic vs. White patients. (C) HRs for overall survival comparing Asian vs. White patients. (D) Odds Rations (ORs) for surgical resection comparing Black vs. White patients.

Year:

2025

Supplemental Table 1 shows specimens by cancer type; Supplemental Figure 1 shows CH variants by patient age; Supplemental Figure 2 shows variant classification by gDNA and plasma variant frequency for gDNA VF ≤ 0.20

Year:

2025

Purpose: To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant (NA) chemotherapy, with and without stereotactic ablative radiotherapy (SAbR), for pancreatic cancer. Insight could clarify the benefits of SAbR and provide molecular guidance for future therapeutic regimens. Experimental Design: This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012 and 2023 treated with NA chemotherapy, with or without SAbR. We compared therapeutic responses, performed patient matching, and conducted Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences. Results: Among 133 patients receiving chemotherapy and 48 receiving chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better posttreatment pathology and similar overall survival [HR = 0.97, 95% confidence interval (CI), 0.58–1.60, P = 0.9]. Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI, 0.07–0.88, P = 0.009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI, 1.74–6.54, P P = 0.005). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control and Treg signatures associated with worse control. Conclusions: NA SAbR is associated with improved pathologic outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. Well-powered studies are needed to clarify its clinical benefits.

Year:

2025

Purpose: Plasma-based liquid biopsy tests can detect tumor-specific genetic alterations and offer many advantages that complement tissue-based comprehensive genomic profiling. However, age-related clonal hematopoiesis (CH) mutations can confound liquid biopsy results and potentially lead to incorrect therapy choice. Experimental Design: We assessed the landscape of 16,812 liquid profiles across 49 cancer types using the Caris Assure assay, a whole-exome and whole-transcriptome next-generation sequencing workflow that independently sequences both plasma-derived cell-free total nucleic acids and the white blood cell DNA and RNA from the buffy coat. The variant source was identified algorithmically by comparing plasma and buffy coat variant frequency and read quality metrics. Results: Of 16,812 patients, 42.3% presented at least one CH variant among reportable clinical genes. We found 39% of BRCA2 variants to be of CH origin, as well as 37.9% of CHEK2 , 27.4% of BRCA1 , 20.1% of ATM , 7.3% of NRAS , 5.8% of BRAF , 2.1% of EGFR , 2.1% of KRAS , and 18.5% of TP53 . For patients aged 65 to 69 years, the median proportion of CH variant classification was 20%, whereas it was 33% for patients aged 70 to 74 years, 33% for ages 75 to 79 years, and 50% for ages 80+ years. We found high rates of CH detected in what would be otherwise druggable targets in many cancer types typically treated with PARP inhibitors, including breast, female genital tract, ovarian, pancreatic, prostate, and endometrial cancers. Conclusions: This large study highlights the need for thorough CH classification during liquid biopsy to appropriately recommend therapies, especially PARP inhibitors. See related commentary by Bernard and Micol, p. 2545

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Collaborators (25)

Chandan Kumar

Associate Research Scientist

University of Michigan

UNITED STATES
View details

George Sledge

-

UNITED STATES
View details

Zhikai Chi

University of Texas Southwestern Medical Center

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Amit G. Singal

-

UNITED STATES
View details

Cheryl Lewis

Associate Professor

University of Texas Southwestern

UNITED STATES
View details

Todd Aguilera

University of Texas Southwestern Medical Center

UNITED STATES
View details

John Mansour

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Adam Yopp

Professor of Surgery

University of Texas Southwestern Medical Center

UNITED STATES
View details

David Zhen

Associate Professor

Montefiore Medical Center

UNITED STATES
View details

Vaibhav Sahai

University of Michigan

UNITED STATES
View details

Song Zhang

-

UNITED STATES
View details

Matthew R. Porembka

University of Texas Southwestern Medical Center

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Madhukar S. Patel

University of Texas Southwestern Medical Center

UNITED STATES
View details

Ahmed M. Elamir

Assistant professor (tenure track) 

East Carolina University

UNITED STATES
View details

Gonzalo Sapisochin

University of Toronto

CANADA
View details

Arathi Mohan

Clinical Assistant Professor

University of Michigan

UNITED STATES
View details

Syed Kazmi

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Nicole Rich

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Patricio M. Polanco

Professor

-

UNITED STATES
View details

Herbert Zeh

Chair of Surgery

University of Texas Southwestern Medical Center

UNITED STATES
View details

Nina N Sanford

University of Texas Southwestern

UNITED STATES
View details

Thomas Enzler

University of Michigan

UNITED STATES
View details

Deepak Nagrath

Professor

University of Michigan

UNITED STATES
View details